Your browser doesn't support javascript.
Reliable and Scalable SARS-CoV-2 qPCR Testing at a High Sample Throughput: Lessons Learned from the Belgian Initiative.
Van Vooren, Steven; Grayson, James; Van Ranst, Marc; Dequeker, Elisabeth; Laenen, Lies; Janssen, Reile; Gillet, Laurent; Bureau, Fabrice; Coppieters, Wouter; Devos, Nathalie; Hengchen, Benjamin; Wattiau, Pierre; Méhauden, Sibylle; Verlinden, Yvan; Van Baelen, Kurt; Pattery, Theresa; Valentin, Jean-Pierre; Janssen, Kris; Geraerts, Martine; Smeraglia, John; Hellemans, Jan; Wytynck, Pieter; Mestdagh, Pieter; Besbrugge, Nienke; Höfer, René; Nollet, Friedel; Vandesompele, Jo; De Smet, Pieter; Lebon, John; Vandewynckele, Emmanuel; Verstrepen, Steven; Uten, Wouter; Capron, Arnaud; Malonne, Hugues; Poels, Jeroen; André, Emmanuel.
  • Van Vooren S; UgenTec, Inc., Cambridge, MA 02138, USA.
  • Grayson J; UgenTec, Inc., Cambridge, MA 02138, USA.
  • Van Ranst M; Department of Microbiology, Immunology and Transplantation, KU Leuven, B-3000 Leuven, Belgium.
  • Dequeker E; Clinical Department of Laboratory medicine and National Reference Center for Respiratory Pathogens, University Hospitals Leuven, B-3000 Leuven, Belgium.
  • Laenen L; Clinical Department of Laboratory medicine and National Reference Center for Respiratory Pathogens, University Hospitals Leuven, B-3000 Leuven, Belgium.
  • Janssen R; Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, University of Leuven, B-3000 Leuven, Belgium.
  • Gillet L; Department of Microbiology, Immunology and Transplantation, KU Leuven, B-3000 Leuven, Belgium.
  • Bureau F; Clinical Department of Laboratory medicine and National Reference Center for Respiratory Pathogens, University Hospitals Leuven, B-3000 Leuven, Belgium.
  • Coppieters W; Clinical Department of Laboratory medicine and National Reference Center for Respiratory Pathogens, University Hospitals Leuven, B-3000 Leuven, Belgium.
  • Devos N; Department of Microbiology, University of Liège, B-4000 Liège, Belgium.
  • Hengchen B; Department of Microbiology, University of Liège, B-4000 Liège, Belgium.
  • Wattiau P; Department of Microbiology, University of Liège, B-4000 Liège, Belgium.
  • Méhauden S; GSK Vaccines, B-1330 Rixensart, Belgium.
  • Verlinden Y; GSK Vaccines, B-1330 Rixensart, Belgium.
  • Van Baelen K; GSK Vaccines, B-1330 Rixensart, Belgium.
  • Pattery T; GSK Vaccines, B-1330 Rixensart, Belgium.
  • Valentin JP; Janssen Pharmaceutica N.V., Johnson & Johnson, B-2340 Beerse, Belgium.
  • Janssen K; Janssen Pharmaceutica N.V., Johnson & Johnson, B-2340 Beerse, Belgium.
  • Geraerts M; Janssen Pharmaceutica N.V., Johnson & Johnson, B-2340 Beerse, Belgium.
  • Smeraglia J; UCB Pharma, B-1420 Braine l'Alleud, Belgium.
  • Hellemans J; UCB Pharma, B-1420 Braine l'Alleud, Belgium.
  • Wytynck P; UCB Pharma, B-1420 Braine l'Alleud, Belgium.
  • Mestdagh P; UCB Pharma, B-1420 Braine l'Alleud, Belgium.
  • Besbrugge N; Biogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.
  • Höfer R; Biogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.
  • Nollet F; Biogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.
  • Vandesompele J; Biogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.
  • De Smet P; Biogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.
  • Lebon J; Biogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.
  • Vandewynckele E; Biogazelle, Technologiepark Zwijnaarde, B-9052 Zwijnaarde, Belgium.
  • Verstrepen S; CliniSys|MIPS, B-9000 Ghent, Belgium.
  • Uten W; CliniSys|MIPS, B-9000 Ghent, Belgium.
  • Capron A; CliniSys|MIPS, B-9000 Ghent, Belgium.
  • Malonne H; CliniSys|MIPS, B-9000 Ghent, Belgium.
  • Poels J; UgenTec n.v., B-3500 Hasselt, Belgium.
  • André E; Sciensano, Belgian Institute for Health, B-1050 Brussels, Belgium.
Life (Basel) ; 12(2)2022 Jan 21.
Article in English | MEDLINE | ID: covidwho-1650548
ABSTRACT
We present our approach to rapidly establishing a standardized, multi-site, nation-wide COVID-19 screening program in Belgium. Under auspices of a federal government Task Force responsible for upscaling the country's testing capacity, we were able to set up a national testing initiative with readily available resources, putting in place a robust, validated, high-throughput, and decentralized qPCR molecular testing platform with embedded proficiency testing. We demonstrate how during an acute scarcity of equipment, kits, reagents, personnel, protective equipment, and sterile plastic supplies, we introduced an approach to rapidly build a reliable, validated, high-volume, high-confidence workflow based on heterogeneous instrumentation and diverse assays, assay components, and protocols. The workflow was set up with continuous quality control monitoring, tied together through a clinical-grade information management platform for automated data analysis, real-time result reporting across different participating sites, qc monitoring, and making result data available to the requesting physician and the patient. In this overview, we address challenges in optimizing high-throughput cross-laboratory workflows with minimal manual intervention through software, instrument and assay validation and standardization, and a process for harmonized result reporting and nation-level infection statistics monitoring across the disparate testing methodologies and workflows, necessitated by a rapid scale-up as a response to the pandemic.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Language: English Year: 2022 Document Type: Article Affiliation country: Life12020159

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Language: English Year: 2022 Document Type: Article Affiliation country: Life12020159